Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis

Autoimmune DiseaseJuvenile Idiopathic Arthritis

Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis

Clin Rheumatol.

Correll CK, Bullock DR, Cafferty RM, Vehe RK

doi: 10.1007/s10067-017-3890-4.

Juvenile Idiopathic Arthritis

2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis

Arthritis Care Res (Hoboken).

Angeles-Han ST, Ringold S, Beukelman T, Lovell D, Cuello CA, Becker ML, Colbert RA, Feldman BM, Holland GN, Ferguson PJ, Gewanter H, Guzman J, Horonjeff J, Nigrovic PA, Ombrello MJ, Passo MH, Stoll ML, Rabinovich CE, Sen HN, Schneider R, Halyabar O, Hays K, Shah AA, Sullivan N, Szymanski AM, Turgunbaev M, Turner A, Reston J

doi: 10.1002/acr.23871.

Juvenile Idiopathic Arthritis

Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study

Rheumatology (Oxford).

Heiligenhaus A, Klotsche J, Tappeiner C, Sengler C, Niewerth M, Liedmann I, Hoeft S, Walscheid K, Lavric M, Foell D, Minden K

doi: 10.1093/rheumatology/key406.

Juvenile Idiopathic Arthritis

Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial

Lancet.

Ravelli A, Davì S, Bracciolini G, Pistorio A, Consolaro A, van Dijkhuizen EH, Lattanzi B, Filocamo G, Verazza S, Gerloni V, Gattinara M, Pontikaki I, Insalaco A, De Benedetti F, Civino A, Presta G, Breda L, Marzetti V, Pastore S, Magni-Manzoni S, Maggio MC, Garofalo F, Rigante D, Gattorno M, Malattia C, Picco P, Viola S, Lanni S, Ruperto N, Martini A; Italian Pediatric Rheumatology Study Group

doi: 10.1016/

Juvenile Idiopathic Arthritis

Long-term outcomes in juvenile idiopathic arthritis: 18 years of follow-up in the population-based Nordic Juvenile Idiopathic Arthritis (JIA) cohort

Arthritis Care Res (Hoboken).

Glerup M, Rypdal V, Arnstad ED, Ekelund M, Peltoniemi S, Aalto K, Rygg M, Toftedal P, Nielsen S, Fasth A, Berntson L, Nordal E, Herlin T, Nordic Study Group of Pediatric Rheumatology (NoSPeR)

doi: 10.1002/acr.23853.

Juvenile Idiopathic Arthritis

Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany

Arthritis Res Ther.

Heiligenhaus A, Klotsche J, Niewerth M, Horneff G, Ganser G, Haas JP, Minden K

doi: 10.1186/s13075-020-02166-3.

Juvenile Idiopathic Arthritis

Juvenile idiopathic arthritis-associated uveitis

Clin Immunol.

Sen ES, Ramanan AV

doi: 10.1016/j.clim.2019.108322.

Juvenile Idiopathic Arthritis

Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry 7-Year Interim Results

Arthritis Care Res (Hoboken).

Brunner HI, Nanda K, Toth M, Foeldvari I, Bohnsack J, Milojevic D, Rabinovich CE, Kingsbury DJ, Marzan K, Chalom E, Horneff G, Kuester RM, Dare JA, Trachana M, Jung LK, Olson J, Minden K, Quartier P, Bereswill M, Kalabic J, Kupper H, Lovell DJ, Martini A, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).

doi: 10.1002/acr.24044.

Juvenile Idiopathic Arthritis

An amino acid motif in HLA-DRβ1 distinguishes patients with uveitis in juvenile idiopathic arthritis

Arthritis Rheumatol.

Haasnoot AJW, Schilham MW, Kamphuis S, Hissink Muller PCE, Heiligenhaus A, Foell D, Minden K, Ophoff RA, Radstake TRDJ, Den Hollander AI, Reinards THCM, Hiddingh S, Schalij-Delfos NE, Hoppenreijs EPAH, van Rossum MAJ, Wouters C, Saurenmann RK, van den Berg JM, Wulffraat NM, Ten Cate R, de Boer JH, Pulit SL, Kuiper JJW

doi: 10.1002/art.40484.

Related content

Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis

2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis

Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study

Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial

Long-term outcomes in juvenile idiopathic arthritis: 18 years of follow-up in the population-based Nordic Juvenile Idiopathic Arthritis (JIA) cohort

Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany

Juvenile idiopathic arthritis-associated uveitis

Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry 7-Year Interim Results

An amino acid motif in HLA-DRβ1 distinguishes patients with uveitis in juvenile idiopathic arthritis